Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation

Leukemia Clinical Trial

Official title:

Efficacy Study About Donor Derived CD19-target T Cell to Treat B-ALL Post Hematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04336501
• Other study ID #: YMCART20190423
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2019
• Est. completion date: December 1, 2021

Study information

• Verified date: December 2020
• Source: Beijing Immunochina Medical Science & Technology Co., Ltd.
• Contact: xiang yu zhao, MD
• Phone: 13520122292
• Email: xyz80421[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation

Description:

Allogeneic hematopoietic stem cell transplantation (allo-hsct) for the treatment of refractory recurrent acute b-lymphoblastic leukemia (b-all), the overall survival rate of 3 years after transplantation was about 10%. The overall survival rate at 3 years was about 70 percent. In the early stage, the investigators established the monitoring method of leukemia micro-residual disease, effectively screened out the high-risk group of recurrence, combined with the new relapse treatment method, successfully implemented the stratification and even personalized dry prediction of leukemia recurrence for the first time in the world, and reduced the recurrence rate of the high-risk group by 30%. However, the therapeutic targeting is not strong, and up to 30% of patients will develop graft versus host disease, which seriously affects the survival of patients. The use of CAR repair T cells (CAR T) to target CD19 in the treatment of refractory recurrent b-all was effective, and the use of CAR T in the treatment of recurrent b-all after transplantation did not increase the risk of GVHD. This clinical study mainly discussed the safety and efficacy of donor targeted cd19-t cells after allo-hsct in the treatment of acute b-lymphocytic leukemia with minimal residual disease. It is expected that the recurrence rate will be reduced while the incidence of acute GVHD after transplantation will not be increase

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 1, 2021
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 65 Years

Eligibility

Inclusion Criteria:

• To be aged 3 to 65 years

• It was consistent with the diagnosis of CD19+ B-All with MRD+ in allo- hsct transplantation

• The immunotyping was determined to be CD19+ B-All

• The T lymphocytes in the subjects were 100% donor T lymphocytes

• No chemotherapy or antibody treatment was received 2 weeks before cell therapy

• Left ventricular ejection fraction (LVEF) =50% and centerless inclusion were diagnosed by echocardiography

• The subjects had no pulmonary active infection

• Blood oxygen saturation at the fingertips = 92%

• Estimated survival of >3 months

• ECOG physical condition level 0~1

Exclusion Criteria:

• Unwilling to accept IM19 CAR-T cell therapy, do not agree to signInformed consent of subject

• Subjects are allergic to the components of cellular products

• Total serum bilirubin = 2.0mg/dl?Serum albumin < 35g/L?ALT and AST were more than 3 times of the upper limit of the normal range. Blood creatinine = 2.0mg/dl;Platelet < 20 x 109 / L

• Subjects had activity level II-IV aGVHD, or activityModerate to severe cGVHD

• The subjects had a severe failure to control the infection

• Subject with known central nervous system leukemia (CNS2 or CNS3)

• Subjects were treated with CAR T cells or DLT after transplantation

• The subjects developed bone marrow failure syndrome after allo-hsct transplantation

• The subjects had previously received other gene treatments

• The subjects had a history of alcohol, drug use or mental illness

• Subjects were enrolled in any other clinical investigator within 1 month prior to screening

• Female subjects: 1) were pregnant/lactating, or 2) had a pregnancy plan during the study period,Or 3) fertile and unable to use effective contraception

• The researchers believe there are other conditions that may not be appropriate for the study

Related Conditions & MeSH terms

• Leukemia

Intervention

Biological:
• IM19 CAR-T
All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later

Locations

Country	Name	City	State
China	Peking University people's hospita	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Immunochina Medical Science & Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR at 6 month	Objective response at 6 month	6 months